Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:SGYP

Synergy Pharmaceuticals (SGYP) Stock Price, News & Analysis

Synergy Pharmaceuticals logo

About Synergy Pharmaceuticals Stock (NASDAQ:SGYP)

Key Stats

Today's Range
N/A
50-Day Range
$0.01
$0.03
52-Week Range
N/A
Volume
N/A
Average Volume
6.08 million shs
Market Capitalization
$7.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Receive SGYP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Synergy Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SGYP Stock News Headlines

Jose Solorio
Is the Trump/Musk duo good for shares of TSLA?
If you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.
Synergy Pharmaceuticals Inc Unit (SGYPU)
Different resistors
Mains cables
See More Headlines

SGYP Stock Analysis - Frequently Asked Questions

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) posted its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.01. The biopharmaceutical company earned $11.11 million during the quarter, compared to the consensus estimate of $15.65 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Synergy Pharmaceuticals investors own include Novavax (NVAX), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), Westmoreland Coal (WLB), ACADIA Pharmaceuticals (ACAD), Cara Therapeutics (CARA) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
11/08/2018
Today
12/17/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SGYP
CUSIP
87163930
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-224,330,000.00
Net Margins
-332.11%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$16.82 million
Book Value
($0.02) per share

Miscellaneous

Free Float
N/A
Market Cap
$7.44 million
Optionable
Optionable
Beta
4.94
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

This page (NASDAQ:SGYP) was last updated on 12/18/2024 by MarketBeat.com Staff
From Our Partners